Atherosclerotic Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Metabolic Health

Background:

• Atherosclerotic cardiovascular disease (CVD) is a leading cause of global morbidity and mortality.
• The American Heart Association introduced a novel framework integrating cardiovascular, kidney, and metabolic health.
• This framework emphasizes the cumulative impact of risk enhancers on major cardiovascular events.

Purpose of the Study:

• To introduce and explain the American Heart Association's cardiovascular kidney metabolic health framework.
• To highlight the role of risk prediction models in early detection of CVD risk.
• To discuss current therapeutic strategies targeting kidney and metabolic pathways for cardiovascular risk reduction.

Main Methods:

• Review of the American Heart Association's cardiovascular kidney metabolic health framework.
• Analysis of risk prediction models for CVD.
• Examination of the current therapeutic landscape for atherosclerotic CVD.

Main Results:

• The framework details a graded accumulation of risk enhancers leading to myocardial infarction, stroke, and peripheral arterial disease.
• Risk prediction models facilitate earlier detection and intervention.
• Therapeutic agents targeting kidney and metabolic pathways demonstrate benefits in reducing cardiovascular events.

Conclusions:

• The cardiovascular kidney metabolic health framework provides a comprehensive approach to understanding CVD risk.
• Early detection and risk reduction are crucial for managing atherosclerotic CVD.
• Targeted therapies offer significant benefits for patients at risk of cardiovascular events.